aldehyde dehydrogenase 3 family member A2Genealiases: ALDH10 · FALDH · SLS
Q-omics provides the consensus-scored ALDH3A2 profile across patient tissues and cancer cell-line models. ALDH3A2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ALDH3A2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ALDH3A2 RNA expression shows 20,246 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where ALDH3A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALDH3A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALDH3A2 survival associations across molecular data types. ALDH3A2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALDH3A2 RNA expression–survival associations across cancer types. High ALDH3A2 expression shows unfavorable associations in OV, but favorable associations in KIRC, BRCA, MESO, KIRP and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ALDH3A2 RNA expression.
This table summarizes ALDH3A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ALDH3A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALDH3A2 shows lower tumor expression in KICH, COAD, LUAD, HNSC, READ and KIRP. The KICH box plot shows higher ALDH3A2 RNA expression in normal versus tumor tissue (log2 FC = −2.342, t-test p < 0.001).
This table shows molecular features associated with ALDH3A2 in patient tissues and cancer cell lines. In patient samples, ALDH3A2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ALDH3A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
